British regulatory authorities have issued an indication to hospitals that people with severe allergies not to get the Pfizer / BioNTech vaccine against Covid-19. The warning came after two British National Health Service officials had allergic reactions after taking the vaccine.
The United Kingdom was the first country to start administering the Pfizer / BioNTech vaccine, this Tuesday, having started the process with the elderly and health professionals who are among the priority groups. It was in two health professionals that it was found that they triggered symptoms of “anaphylactic reaction” shortly after they had the vaccine. According to Sky News, both are already recovering and both have a history of severe allergies, to the point of having to carry the adrenaline pen for SOS situations.
In view of these two cases, the Regulatory Agency for Medicines and Health Products (MHRA) issued a preventive alert so that the vaccine is not administered to anyone who has a history of severe allergies, whether it is allergies to drugs or food products.
According to Sky News, the British SNS has already made it known that all entities involved in the vaccination program have been informed of this situation and, as of Wednesday, all patients who will receive the Pfizer vaccine will be asked, first, if they have a history of allergic reactions .
A Pfizer spokesman has already responded to the cases, stating that no allergy-related problems were detected in clinical trials, but as a preventive measure, the pharmacist supports the regulator’s decision to stop vaccination in this age group with a history of allergies severe.
“We were informed by the health regulator of two reports associated with an allergic reaction to the vaccine. As a preventive measure, the MHRA issued temporary guidelines to the National Health Service ”to stop vaccinating these people, until an investigation into the causes of the allergic reaction is complete. Research that the pharmaceutical company supports: “Pfizer and BioNTech are supporting MHRA research”.
“In phase three of the clinical trials, the vaccine was generally positively tolerated, with no safety problems detected by the independent committee that analyzed the data,” says Pfizer in a statement, recalling that the testing phase involved 44,000 participants and more 42 thousand have already received the second dose.
–
